Recent trends in systemic psoriasis treatment costs

Area of Science:

• Dermatology
• Health Economics

Background:

• Psoriasis is a chronic inflammatory skin condition requiring long-term systemic therapy.
• Understanding the economic burden of psoriasis treatment is crucial for healthcare planning and patient access.

Purpose of the Study:

• To analyze the current total cost of systemic therapy for psoriasis.
• To compare annual cost trends of generic and brand-name psoriasis therapies with the Consumer Price Index-Urban (inflation) from 2000 to 2008.

Main Methods:

• A cost model was developed, incorporating prescription drug costs, office visits, and laboratory monitoring.
• Annual trends in psoriasis drug costs were analyzed using average wholesale price percentage changes.
• Psoriasis drug cost trends were compared with Consumer Price Index-Urban values.

Main Results:

• Current annual systemic psoriasis therapy costs range from $1,197 (methotrexate) to $27,577 (alefacept).
• Brand-name psoriasis therapies saw an average price increase of 66% between 2000 and 2008.
• The cost of several brand-name psoriasis drugs significantly outpaced inflation.

Conclusions:

• Biologic therapies for psoriasis have higher annual costs than other systemic treatments.
• Systemic psoriasis therapy costs are increasing at a rate substantially higher than general inflation.
• Rising costs may affect treatment accessibility and adherence for psoriasis patients.